NHS England, NICE & Vertex Have ‘Forgotten Patients’ In Orkambi Impasse
Executive Summary
Vertex, NHS (National Health Service) England, and the health technology appraisal body NICE have forgotten about patients in the impasse over access to cystic fibrosis drug Orkambi, says a patient representative who attended the recent hearing on the price of the drug.
You may also be interested in...
UK Rare Disease Drug Review Reform Urged As Spinraza Finally Gets NICE OK
It has taken 17 months of negotiations but soon 600-1,200 people in the UK may be able to get Biogen's spinal muscular atrophy therapy now that an access agreement has been inked.
UK NICE To Pharma Firms: Up Your Game In Horizon Scanning
Pharmaceutical companies must play a fuller part in planning for health technology appraisals by NICE, which has resource limitations and cannot do everything that companies might expect of it, a recent workshop in London heard.
‘Extreme Outlier’ Vertex Slammed For Orkambi Pricing Approach In England
Vertex has come under fire for its alleged extreme rigidity on pricing for its cystic fibrosis drug in England.